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Bronchopulmonary dysplasia (BPD) remains a significant clinical challenge in neonatal
medicine. BPD is clearly a multifactorial disease with numerous antenatal and postnatal
components influencing lung development. Extremely immature infants are born in the
late canalicular or early saccular stage and usually receive intensive care until the early
alveolar stage of lung development, resulting in varying magnitudes of impairment of
alveolar septation, lung fibrosis, and abnormal vascular development. The interactions
between T lymphocytes, the genome and the epigenome, the microbiome and the
metabolome, as well as nutrition and therapeutic interventions such as the exposure
to oxygen, volutrauma, antibiotics, corticosteroids, caffeine and omeprazole, play an
important role in pathogenesis and disease progression. While our general understanding
of these interactions thanks to basic research is improving, this knowledge is yet to
be translated into comprehensive prevention and clinical management strategies for
the benefit of preterm infants developing BPD and later during infancy and childhood
suffering from the disease itself and its sequelae. In this review, we summarise existing
evidence on the interplay between T lymphocytes, lung multi-omics and currently used
therapeutic interventions in BPD, and highlight avenues for potential future immunology
related research in the field.
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INTRODUCTION
The progressive, preferential maturation of the neonatal adaptive immune system is driven by
multi-omic interactions in-utero and after birth. Together, these shape health and disease in
the newborn and infant. After birth, the neonatal adaptive immune system needs to fulfil the
requirements of two distinct developmental needs. On one hand, it needs to recognise and eliminate
pathogens to prevent infections. On the other hand, it needs to establish tolerance towards harmless
antigens and bacteria that will form the microbiome at various mucous membranes of the body (1).
This delicate developmental program may be influenced by several factors, such as the external
environment, prematurity, and measures provided to ensure survival. These factors can easily shift
the fine-tuned balance that aims tomaintain the progression of both immunological developmental
needs at the same time. While our understanding of such interactions in the context of the gut
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microbiome and necrotising enterocolitis is improving (2),
there is still a substantial knowledge gap around the role
of the immune—microbiome, and multi-omic interactions in
contributing to the development of other pathologies, such
as bronchopulmonary dysplasia (BPD). This complex lung
condition is becoming increasingly prevalent especially among
extremely preterm neonates due to the decreasing gestational age
thresholds for survival (3).
A recent comprehensive review by Thebaud et al. summarised
the essence of the pathophysiology of BDP as the “impaired
postnatal adaptation of the preterm lungs to breathing challenged
by initial lung injury due to surfactant deficiency, exposure
to hyperoxia, mechanical ventilation, inadequate nutrition,
infection and inflammation, which together provide considerable
hurdles to normal pulmonary growth and repair and result in a
loss of effective alveolar surface area” (4). Lal et al. have lately
suggested that BPD is unlikely to be a single entity, or even a
spectrum of disease with the same pathophysiologic background.
The common denominator is the affected population of
premature infants in the late canalicular, saccular or early
alveolar stage of lung development, resulting in varying degree
of alveolar septation impairment, lung fibrosis, and abnormal
vascular development (5). Instead of a single chain of events, an
interplay between the immune system, the genome, epigenome,
microbiome, proteome, metabolome, and environmental factors,
such as oxygen, mechanical ventilation andmedication including
antibiotic therapy, may contribute to the pathogenesis to
different degrees. The pathophysiology of BPD may be deeply
intertwined with these multi-omic interactions. The potential
importance of immune-mediated mechanisms guiding these
interactions leading to and responsible for recovery from
lung damage are poorly understood and necessitate future
immunological research in this area.
The diverse population of T lymphocytes is the cornerstone of
adaptive immunity. They play a key role not only in recognising
and eliminating pathogens, but also in coordinating tissue
inflammatory responses and repair. The functional heterogeneity
of T cells allows for a fine-tuned control system engaging both
pro- and anti-inflammatory mechanisms mediated by relevant T
lymphocyte subsets.
In this review, we summarise existing evidence on the
interplay between T lymphocytes, lung multi-omics, currently
used therapeutic interventions and BPD. We aim to visualise
this disease through the lens of an immunological approach
and highlight avenues for potential future immunology related
research in BPD.
T LYMPHOCYTES
Limited studies in human neonates show some alteration in T
lymphocyte numbers, activation and regulation in preterm babies
who develop BPD. Ballabh et al. compared the proportion of
lymphocyte subsets using flow cytometry in preterm infants with
RDS who later developed BPD in comparison with those who
did not. The absolute number of lymphocytes and CD4 cells was
lower among infants with BPD over the first 2 weeks of life The
proportion of CD8 and NK cells was not different between the
two groups. The proportion of B cells was decreased in BPD
infants only on day 7. The proportion of CD4 cells expressing
CD62L was selectively reduced in BPD infants, indicating L-
selectin shedding, a marker of T cell activation (6). In a similar
study, Turunen et al. reported that in preterm infants with
RDS, the increased proportion of activated T cells predicted the
development of BPD. RDS infants who subsequently developed
BPD had higher CD54 activationmarker expression on CD4 cells
on day 3 of life and on CD8 cells on days 1 and 3 of life as
compared with infants without BPD (7).
Jackson et al. analysed blood samples drawn from preterm
infants born at 28 weeks of gestation or less at the first, second,
and fourth week of life. Leukocytes isolated from infants who
developed BPD had increased PMA/ionomycin stimulated and
unstimulated IL-4mRNA expression at the first week of life, while
that of IFN-g was comparable. The expression of IL-2 was also
decreased in infants developing BPD, however, this difference
was more sustained. The Th17 and regulatory T cell immune
profile was comparable in infants who developed BPD and in
those who did not (8). On the contrary, in cord blood samples
of infants born at 32 weeks of gestation or less, Misra et al.
identified a decrease in CD4 cells and CD4+ FoxP3+ CD25+
CD127lo regulatory T cells using flow cytometry in those who
later developed BPD (9).
Using a baboon model, Rosen et al. investigated whether
autoreactive T cells could contribute to lung injury in BPD.
In their functional studies, they performed mixed lymphocyte
reactions using thymocyte or splenocyte responders with
autologous lung cells as the stimulators. BPD thymocytes
and splenocytes showed an increased proliferative response to
autologous lung cells compared to controls. 2A11, an anti-
bombesin antibody known to protect against BPD in baboons,
normalised this response and the generation of autoreactive T
cells that could contribute to lung injury (10).
The abundance of IL-1 strongly correlates with the long-
term outcome and severity of BPD. Nold et al. demonstrated
that the anti-inflammatory IL-1 receptor antagonist (IL-1Ra)
prevented BPD precipitated by lipopolysaccharide and hyperoxia
in a murine model. IL-1Ra treatment for 28 days inhibited
the evolvement of histological changes characteristic for BPD
(11). Furthermore, it also prevented the increase in pulmonary
vascular resistance and pulmonary dysangiogenesis. Importantly,
this protection against pulmonary hypertension was maintained
at day 60 of life in mice (12).
The human lung harbours CD4+ and CD8+ tissue resident
memory T cells (TRM) that persist in stable frequencies for
decades throughout the individual’s lifespan. Studies in adults
revealed their important contribution to pathogen defence, tissue
homeostasis and immune surveillance. They also play a role in
promoting inflammation in asthma (13). During infancy, naive T
cells represent the predominant population not only in peripheral
blood but also in the lungs (14). With repeated pathogen and
harmless environmental antigen exposures through inhalation
and aspiration, effector memory T cells outnumber naïve T cells
in the lung by late childhood, along with coincident expression
of TRM phenotypes (15). In spite of their important role in lung
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pathology, probably due to difficulties of tissue sample collection
from preterm patients, their contribution to the pathogenesis of
BPD has not been elucidated.
Most of the alterations observed in lymphocyte subsets
and cellular or humoral biomarkers have been shown to have
poor predictive accuracy, and do not considerably improve
the predictive ability of clinical variables, such as gestational
age, birth weight or respiratory parameters (5) in relation to
the development of BPD. On the other hand, most of these
observational studies were not designed or powered to assess the
predictive value of these markers. The application of the latest
multi-omic approaches might provide added insights towards
understanding the immune mechanisms by which BPD develop.
In doing so, it could contribute towards fine tuning immune
based predictive markers for the development, prevention and
limitation of the severity of BPD in premature neonates.
MULTI-OMIC INTERACTIONS
Genome and Epigenome
Pietrzyk et al. compared whole genome expression using
microarrays in blood samples of preterm infants with and
without BDP on days 5, 14 and 28 of life. Two thousand eighty
six genes were differentially expressed on day 5, while 324 on
day 14 and 3,498 on day 28, respectively. Pathway enrichment
analysis revealed that the cell cycle pathway was up-regulated in
BPD. Four pathways related to inflammatory response (T cell
receptor signalling, primary immunodeficiency, hematopoietic
cell lineage, and cell adhesion molecules) were down-regulated
in BPD at all three time points. The expression of these genes
correlated with both immaturity and disease severity. The most
significantly down-regulated pathway was the T cell receptor
signalling pathway (16).
Revhaug et al. examined the regulatory relation between
immune gene expression and DNA methylation after hyperoxia
for 14 days followed by a recovery period of 14 days in air using
a neonatal mouse model of BPD. A high proportion of immune
genes showed significant alterations in expression. For instance, B
cell genes involved in the cytokine-cytokine receptor interaction,
the PI3K-AKT, and the B cell receptor signalling pathways
were found to be altered. They also observed significant DNA
hypermethylation in the PI3K-AKT pathway and other immune
genes. Some of these could also influence the differentiation
and function of the T lymphocyte subset. The genomic and
epigenomic influence of oxygen exposure could therefore play a
role in the pathogenesis of BPD and the increased susceptibility
to respiratory infections seen in premature babies with BPD (17).
Further work is needed to explore consistent patterns of the
contribution genomic and epigenomic changes of T lymphocytes
and other immune cells to the pathogenesis of BPD.
Microbiome and Metabolome
The airway microbiome evolves over time with increasing
bacterial loads and diversity. Staphylococcus, Ureaplasma and,
according to some reports, Acinetobacter are the predominant
genera early after birth. BPD is associated with increased
microbial community turnover. Alterations in the relative
abundance of Proteobacteria and Firmicutes, and decreased
Lactobacilli were reported with the progression of BPD (18, 19).
Lal et al. reported an established diverse airway microbiome
at birth in both preterm and term infants (20). Older infants
with BPD had reduced airway microbial diversity (18, 20). The
presence of members of the phylum Proteobacteria, such as
E. coli, was associated with BPD pathogenesis. Furthermore,
genus Lactobacillus was decreased at birth in infants with
chorioamnionitis, an independent risk factor for BPD, and
in preterm infants who subsequently developed BPD. Genus
Lactobacillus is known to have anti-inflammatory properties in
the airway (21) and was shown to regulate alveolar development
in a mouse model (22).
The authors concluded that their results may suggest foetal
acquisition of an airway microbiome which may prime the
developing pulmonary immune system. Although based on
earlier reports it was indeed presumed that the human placenta
may harbour a microbiome, and, therefore the womb and the
intrauterine environment may not be sterile, recent extensive
work by de Goffau et al. elegantly demonstrated that the human
placenta is in fact sterile and has no microbiome (23). Signals
detected in non-culture based microbiological experiments were
most likely related either to sampling issues, for instance,
the acquisition of bacteria during labour and delivery, or to
contamination of laboratory reagents with bacterial DNA. These
limitations need to be cautiously taken into account when
interpreting results from these reports and their implications on
the potential antenatal development of airway microbiome in
the foetus.
The lung microbiome was described to interact with the
immature immune system by inducing the expression of CD274,
a B7-family antigen on pulmonary dendritic cells, eliciting
inhibition of T cell activation via CD279 (also known as PD-1
receptor) on T cells. Blocking pulmonary CD274 during the first
2 weeks of life induced a disproportionate inflammatory response
to allergens later in life in mice (24).
The same group later reported plausible mechanisms by
which the airway microbiome could modify the risk for BPD
by identifying differentially abundant functional orthologue
genes in infants predisposed to BPD and controls. They also
identified metabolites that were differentially enriched in the two
cohorts. Specific pathways were less abundant in the functional
metagenome of the microbiota of BPD-predisposed infants
compared to controls. Furthermore, the airway metabolome of
BPD-predisposed infants was enriched for metabolites involved
in fatty acid activation and androgen and oestrogen biosynthesis.
These findings suggest that the early airway microbiome may
alter the metabolome, thereby modifying the risk of BPD. They
may also account for the previously described male gender
predilection of BPD (25).
Another important mechanism via which the microbiome
can influence immune cell function is through the production
of microbial metabolites, including short chain fatty acids
or tryptophane catabolites. Short chain fatty acids, in
particular propionate and butyrate, are known to play an
important role in promoting regulatory T cell differentiation
and proliferation via the inhibition of histone deacetylases
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(26). Indoleamine 2,3-dioxygenase is responsible for the
production of tryptophane catabolites which, amongst other
functions, act as agonists for the aryl hydrocarbon receptor
(AhR). AhR activation facilitates immune suppression
through the production of IL-22 and also promotes the
development of regulatory T-cells. A bacterial genus
capable of metabolising tryptophane into AhR agonists are
Lactobacilli (27).
Omeprazole was shown to achieve the same effect as
tryptophane catabolites by inducing CYP1A1 possibly through
an AhR-mediated process. Combined pre- and postnatal
administration of omeprazole attenuated hyperoxic lung injury
evoked in preterm rabbits (28). AhR signalling was found
to be protective against hyperoxic injury in human foetal
pulmonary microvascular cells and neonatal mice mediated
by gene expression of immunomodulatory and developmental
pathways (29).
Shivanna et al. tested whether omeprazole attenuated
hyperoxia-provoked lung injury in adult mice by inducing
CYP1A1 by activating pulmonary AhRs. Attenuation of lung
injury by omeprazole paralleled enhanced pulmonary CYP1A1
in omeprazole treated mice. Omeprazole failed to enhance
pulmonary CYP1A1 expression and protect against hyperoxic
lung injury in AhR deficient mice (30). The same group went
on to elucidate whether omeprazole protects against hyperoxia-
induced lung injury in a neonatal mouse model of BPD by
supposedly activating pulmonary AhRs. Surprisingly, in the
neonatal period, hyperoxia-induced alveolar and pulmonary
vascular simplification, inflammation, oxidative stress, and
vascular injury were augmented rather than mitigated in
omeprazole-treated animals. These findings were associated with
decreased rather than increased pulmonary AhR activation (31).
Segal et al. revealed in their study that azithromycin increased
levels of tryptophan catabolites in bronchoalveolar lavage fluid
of smokers who developed emphysema, thus reducing the
production of pro-inflammatory cytokines (32). Besides its
potent anti-inflammatory properties, azithromycin is also known
to be highly effective against Ureaplasma, a likely contributor
to BPD pathogenesis. However, earlier trials on its use for
the prevention of BPD were not adequately powered. In a
randomised phase II trial of preterm infants between 24+0 and
28+6 weeks of gestation, a three-day course of azithromycin
improved Ureaplasma-free survival and showed a promising
trend towards a shorter exposure to invasive ventilation and
supplemental oxygen and a shorter duration of hospitalisation
(33). A currently ongoing RCT, the AZTEC study aims to
investigate if a 10-day course of azithromycin improves rates of
survival without CLD when compared with placebo (34).
There is increasing evidence on the role of the airway
microbiome in BPD. However, these studies may have sampling
and methodological limitations which should be observed when
interpreting the results.
Gut-Lung Axis
Epidemiological studies have linked perinatal antibiotic exposure
in human newborns to an increased risk for BPD, possibly
mediated through the gut-lung axis (35, 36). A recent important
report on the gut-lung axis illuminated that intestinal commensal
bacteria prevent pneumonia by promoting the trafficking of IL-
22-producing group 3 innate lymphoid cells (ILC3) into the lung
of newborn mice (37). The high level of IL-22 inhibits pathogen
proliferation and regulates granulocyte colony-stimulating factor
production in the lung (38). This trafficking is dependent on
the presence of an intestinal microbiome and is mediated by
CD103+CD11b+ intestinal dendritic cells that induce CCR4
homing receptor overexpression on intestinal IL-22+ ILC3. A
chemokine expressed in the lung epithelium, CCL17, activates
the CCR4 receptor. Thus, it promotes the trafficking of IL-22+
ILC3 into the lung. The authors confirmed these observations
in a cohort of 15 human neonates treated with antibiotics
and having a history of mechanical ventilation, finding reduced
concentrations of IL-22 in their BAL fluid samples (37). The vast
majority of IL-22 producers in both pups and human infants
were ILC3s, in contrast with NK, Th17 and γδ T cells previously
reported in adults (39–41).
Willis et al. have recently shown how perinatal maternal
antibiotic exposure influenced lung injury in a hyperoxia-based
mouse model of BPD. Antibiotic-induced intestinal dysbiosis
during the perinatal period promoted a more severe BPD
phenotype characterised by increased pulmonary fibrosis and
overall mortality. This was associated with decreased IL-22
expression in bronchoalveolar lavage and was independent
of hyperoxia-induced inflammasome activation. The results
emphasise the transgenerational disruptive effects of antibiotic
exposure on the inflammatory balance in the lung (42).
INTERVENTIONS
Hyperoxia
While the provision of increased FiO2 is often necessary
to ensure adequate tissue oxygenation in the preterm
neonate, hyperoxia is known to have harmful pulmonary
and extrapulmonary consequences and is associated with
increased oxidative stress (43), morbidity, such as retinopathy of
prematurity (44–46) and mortality (47). Oxygen levels influence
both the developing microbiome and immune system, and we
have gained increasing understanding of these interactions over
the recent years. Anaerobic bacteria do not tolerate high levels of
oxygen, thus hyperoxia can confer a selective growth advantage
on aerobic bacterial species within the microbiome. Innate
immune cells heavily rely on the generation of reactive oxygen
and nitrogen species to elicit a response against pathogens
and other stimuli. Therefore, inflammatory lung conditions
are characterised by high levels of oxidative stress. The role of
oxidative stress in the development of BPD is comprehensively
reviewed by Capasso et al. (48).
In a mouse study, Kumar et al. demonstrated that neonatal
hyperoxia suppresses the expression of genes involved in T and B
cell activation, an effect still detectable in adulthood at 3 months.
Newborn mice litters were exposed at 3 days to 85% O2 or room
air for a period of 12 days. Whole lung mRNA was isolated at
2 weeks and 3 months. Further to the gene expression changes,
adult mice exposed to neonatal hyperoxia also had lower levels of
anti-inflammatory IL-4 and IL-10 in the lung at 3 months (49).
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Ashley et al. investigated the effects of hyperoxia on the gut
and lung microbiome in mice and human samples (50). In an
observational study of critically ill patients receiving mechanical
ventilation, as well as in experiments on neonatal and adult
mouse models, they demonstrated that hyperoxia was associated
with a selective growth advantage on oxygen-tolerant respiratory
microbial species, such as S. aureus. During exposure of mice
to hyperoxia, both the lung and gut microbiome was altered,
and this preceded and contributed to oxygen-induced lung
injury. Compared to normoxia, lungs of hyperoxia-exposed mice
had decreased community richness and had increased relative
abundance of an oxygen-tolerant Streptococcus species, and
variations in lung and gut microbiota correlated with the severity
of lung inflammation. Systemic treatment with broad Gram-
negative spectrum antibiotics, ceftriaxone, selectively increased
the severity of oxygen-induced lung injury as measured by
alveolar protein excretion. Interestingly, germ-free mice were
protected from oxygen-induced lung injury.
The authors highlighted that the specific contributions of
lung and gut microbiota to the above effects are not fully
understood. The same group demonstrated earlier that variation
in lung innate immunity more strongly reflected lung than gut
microbiota in mice (51). In the hyperoxia study, variation in
lung inflammation correlated with the diversity and community
composition of both lung and gut microbial communities,
but correlation with lung microbial communities preceded
correlation with gut microbial communities (24 vs. 48 h).
Therefore, most likely both the gut and lung microbiome play
important, temporally distinct roles in the pathogenesis of
oxygen-induced lung injury.
Early airway dysbiosis and the disruption of the development
of a normal pulmonary microbiome are associated with
the development of BPD. In a recent study, Dolma et al.
investigated how hyperoxia and a complete lack of microbiome
in germ-free mice influenced pulmonary alveolar and vascular
development in comparison to control non-germ-free mice.
They studied alveolar morphometry, pulmonary mechanics,
echocardiograms, inflammatory markers, and measures of
pulmonary hypertension. Germ-free and control mice in
normoxia showed no difference in these parameters. In
hyperoxia, however, germ-free mice had protected lung
structure and mechanics and decreased markers of inflammation
compared with controls (52).
Hyperoxia evokes direct effects on T lymphocyte function but
also influences the composition of the microbiome, conferring
further effects on the pathogenesis of BPD. While providing
higher oxygen levels is often a necessary intervention to
ensure survival, understanding these effects may open up novel
therapeutic avenues.
Corticosteroids
Corticosteroids are probably the most common effective
immunomodulatory therapy for BDP routinely used in clinical
practice. They exert anti-inflammatory and immunosuppressive
properties by inducing the activity of anti-inflammatory
mediators and by directly suppressing T cell proliferation and
function, respectively.
Parimi et al. analysed the effect of dexamethasone treatment
on peripheral blood lymphocyte counts and subsets in preterm
infants with BPD before, on days 3 and 10 and 2 weeks after
treatment using flow cytometry. The absolute number and
percentage of lymphocytes, T cells, and CD4 cells, as well as
the CD4/CD8 ratio were significantly reduced by dexamethasone
by day 3 of treatment. A reduction in CD4 cells and in the
CD4/CD8 ratio persisted 2 weeks after therapy was discontinued.
The absolute number of B cells increased transiently, while CD8
cells were unaffected by dexamethasone (53).
To better understand the long-term immune and endocrine
effects of neonatal corticosteroid treatment for BPD, Karemaker
et al. performed a retrospective matched cohort study among
prematurely born children who were treated either with
dexamethasone or hydrocortisone or received no corticosteroids
in the neonatal period. Following in vitro stimulation, the ratio
of T cell IFN-g/IL-4 secretion was significantly higher in the
dexamethasone group than in the hydrocortisone or control
groups between 8 and 9 years of age. The production of IFN-g,
IL-4 and IL-10 did not differ between the hydrocortisone and the
control groups. The adrenocorticotropic hormone response to an
age-adapted stress test was blunted in the dexamethasone group.
The results demonstrate that neonatal treatment of prematurely
born children with dexamethasone but not with hydrocortisone
resulted in long-lasting effects on the Th1/Th2 cytokine balance
and on the hypothalamus-pituitary-adrenal axis (54).
Although corticosteroids have long been used in the clinical
setting for the treatment of BPD, their effect on T lymphocyte
function and multi-omic interactions in this condition merits
further investigation.
Caffeine
The CAP trial demonstrated that caffeine reduces the incidence
of BPD (55). However, the underlying mechanisms are poorly
understood. Originally, the beneficial effect was presumed to
be related to a reduction of ventilatory days secondary to
increased respiratory drive and promoting diuresis and thus
facilitating extubation, but emerging evidence also suggests
an immunomodulatory effect. Deregulated TGF-b signalling
underlies arrested postnatal lung maturation in BPD (56). Rath
et al. examined the impact of caffeine on TGF-b signalling in
primarymouse lung fibroblasts and alveolar epithelial type II cells
in vitro. They also assessed the effect of caffeine administration in
the first 14 days of life in vivo in a hyperoxia-triggered neonatal
mouse model of BPD. While caffeine reduced the expression
of type I and type III TGF-b receptors and increased TGF-b
signalling in vitro, caffeine administration neither improved nor
worsened lung structure in hyperoxia-exposed mice (57). On the
contrary, another group showed that in a similar mouse model
following 4 days of caffeine administration, caffeine modulated
angiogenic gene expression and ameliorated the pulmonary
microvasculature and alveolarisation (58).
Further studies are needed to describe the beneficial
impact of caffeine administration in the context of BPD
pathophysiology, including its effect on the inflammatory
response and tissue remodelling.
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FIGURE 1 | Summary of the multi-omic interactions as well as the influence of therapeutic and care interventions governing T cell function in bronchopulmonary
dysplasia. The numbers on the arrows reflect the relevant literature in the reference list. TRM, tissue resident memory T cell.
Nutrition and Breastfeeding
Information on the influence of nutrition, and in particular,
breastmilk on T lymphocytes and multi-omic interactions
in BPD is extremely limited. Studies to date have mostly
focused on the nutritional impact of breastfeeding in BPD.
Neonates with BPD have higher nutritional (protein, calcium,
phosphorus and vitamin D) and energy requirements compared
to preterm babies without BPD due to 15–25% increased
energy expenditure related to work of breathing. Importantly,
corticosteroid treatment may alter protein metabolism and the
composition of weight gain and reduce bone mineralisation
(59). Infants born small for gestational age and those with
postnatal growth failure are more likely to develop BPD (60).
However, specific components of parenteral nutrition, for
example intravenous lipid emulsions, can also increase the
risk of BPD, possibly through its influence on inflammatory
pathways. A recent case-control study in infants born at
<32 weeks of gestation or with a birth weight of <1,500 g
demonstrated that infants who developed hypertriglyceridemia
following parenteral nutrition had a two-fold increased
incidence of BPD and longer duration of mechanical ventilation
compared to controls (61). Accordingly, the authors suggest
temporary suspensions or reduction of lipid intake in case
hypertriglyceridemia develops.
Our group has recently demonstrated that breastfeeding
significantly impacts T cell development in the first 3 weeks of
life and promotes the expansion of regulatory T cells in the
circulation of breastfed term neonates compared to formula-
fed babies. Furthermore, breastfed neonates showed a specific
and Treg-dependent reduction in proliferative T cell responses
to non-inherited maternal antigens (62). Tregs may play an
important role in reducing the inflammatory response associated
with BPD, and neonates who developed BPD were shown to
have a lower prevalence of peripheral Tregs compared to non-
BPD neonates (9). Therefore, besides its nutritional benefits,
breastfeedingmay have a positive impact on the incidence of BPD
exploiting this and possibly other, yet undiscovered mechanisms.
Indeed, Xu et al. have recently reported that a daily threshold
amount of 50 ml/kg/day or more of human milk in the first 4
weeks of life was associated with lower incidence of BPD (63).
Microaspirations
Farhath et al. demonstrated increased pepsin concentrations
in tracheal aspirates of intubated preterm infants who later
developed BPD in comparison to those who did not. Recovery of
pepsin in tracheal aspirates was secondary to gastric aspiration,
not to hematogenous spread or local synthesis in the lungs
(64). The authors suggested that chronic aspiration of gastric
contents may contribute to the pathogenesis of BPD, however,
the mechanism remains unclear. Theoretically, the translocation
of components of the gut microbiome with aspiration (the
gut—lung axis) and the acidity of gastric contents provoking
pneumonitis may both play a role in T cell activation and
dysfunction, and eventually in the pathogenesis of BPD.
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FUTURE DIRECTIONS
The following is a non-exhaustive list of future research priorities
in the pathophysiology of BPD. These points all have relevance
from a multi-omics perspective and address pressing questions
that will expand our understanding of this disease.
• An in-depth, systems level profiling of T cell subsets and
development is needed, that will characterise the dynamics
and interactions of this subset with other immune and non-
immune cells. Single cell methods and a multi-omics approach
will be particularly relevant to achieve this goal. The results
from such studies will also help identify future predictive and
therapeutic targets for various aspects of the development and
progression of BPD.
• There are several limitations of studying the in vivo
interactions on the tissue level in the premature lung. Animal
studies will not necessarily be able to address all of these
shortcomings. For instance, our knowledge on the role and
function of TRM cells in BPD is particularly limited. While
the lack of live tissue sampling from patients will remain
a limitation, single-cell and multi-omic methods have the
potential to answer questions regarding this important T
cell population.
• Further effort is needed to identify the interactions
between inflammatory mediators, the lung microbiome
and mechanisms governing pulmonary tissue and vessel
formation in the developing lung of preterm infants.
The complex influences of multi-omic interactions on
alveolarisation and vessel growth in prematurity, as well as the
impairment of these processes resulting in reduced effective
alveolar surface area and pulmonary hypertension in BPD
merit in-depth investigation.
• The importance of the gut—lung axis has only recently
been recognised in BPD. The role of breastfeeding and
microaspirations as possible protective and exacerbating
factors, respectively, require more detailed investigation.
The underlying immunological mechanisms and multi-omic
interactions deserve further attention.
• Finally, as our clinical knowledge on therapeutic approaches
in BPD grow, a multi-omics approach should be employed
in order to discover how normal lung development and
current and future therapies—such as oxygen, antibiotics,
dexamethasone, hydrocortisone, sildenafil and bosentan—
influence the pathogenesis of and recovery from BPD.
CONCLUSIONS
In this review, our current understanding of adaptive immunity,
specifically T lymphocyte development and function in relation
to BPD is discussed. Interactions on several levels, with
genome, epigenome, microbiome, metabolome, environmental
and medical interventional factors appear to impact on this
component of the immune system in BPD (Figure 1). As a
disease of immaturity, with damage and repair mediated by
a combination of multi-omic factors that work contiguously,
it is becoming more important to understand this interplay,
and the immune-mediated contribution to lung protection. A
multi-omic approach is likely to be useful in future research on
BPD. Immunological insights that enhance our understanding of
the development of BPD, and augment the predictive value of
clinical profiles of BPD in at-risk preterm neonates, may prove
useful adjuncts to clinical care in the future, both for prevention
and treatment of BPD.
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